Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.43 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7510160 | 0.86 | CYP3A4 (0.41) | ERN1MAPTTDP1LMNAMEN1 | |
| SCHEMBL12104188 | 0.83 | GPR35 (0.49) | ERN1MAPTTDP1MEN1KMT2A | |
| SCHEMBL28824827 | 0.81 | MAPT (0.43) | ERN1MAPTTDP1LMNAMEN1 | |
| SCHEMBL15783807 | 0.81 | TDP1 (0.44) | ERN1MAPTTDP1VCAM1GPR35 | |
| SCHEMBL15776986 | 0.81 | MAPT (0.47) | ERN1MAPTTDP1LMNAMEN1 | |
| SCHEMBL31730320 | 0.81 | ERN1 (0.65) | ERN1MAPTTDP1LMNAMEN1 | |
| SCHEMBL11210616 | 0.81 | ERN1 (0.65) | ERN1MAPTTDP1LMNAMEN1 | |
| SCHEMBL9452603 | 0.81 | TSHR (0.59) | MAPTTDP1LMNAMEN1HTT | |
| SCHEMBL29005655 | 0.78 | TSHR (0.56) | ERN1MAPTTDP1LMNAMEN1 | |
| SCHEMBL13955634 | 0.78 | CYP3A4 (0.72) | MAPTTDP1LMNAVCAM1GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113214182-B | Benzisothiazole compound and preparation method thereof | 佛山湘潭大学绿色智造研究院 | 2022-12-23 | — | — | CN | disclosed |
| CN-106536489-B | Retinoid-related orphan receptor gamma modulators and uses thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-3148975-B1 | PIPERAZINE DERIVATIVES AS ROR-GAMMA MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| WO-2015180612-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-4456772-A | Process for the preparation of optionally substituted fluoro-nitro-benzaldehydes | BAYER AKTIENGESELLSCHAFT (DE) | 1984-06-26 | — | — | US | disclosed |
| EP-0061113-B1 | METHOD FOR THE PREPARATION OF OPTIONALLY SUBSTITUTED FLUORONITROBENZALDEHYDES | BAYER AG (DE) | 1984-06-06 | — | — | EP | disclosed |
| EP-0061113-A1 | Method for the preparation of optionally substituted fluoronitrobenzaldehydes | BAYER AG (DE) | 1982-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197978-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | ERN1 2621/4885MAPT 3279/4885TDP1 4606/4885 |
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | ERN1 1414/4885MAPT 4075/4885TDP1 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.